SWOG clinical trial number
SWOG-9011
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Hodgkin's Disease
Closed
Phase
Accrual
90%
Published
Abbreviated Title
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Hodgkin's Disease
Activated
04/15/1990
Closed
12/01/1995
Research committees
Lymphoma
Publication Information Expand/Collapse
2003
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial
1996
Single fraction high dose chemotherapy with or without total body irradiation (TBI) and an autologous bone marrow transplant (ABMT) for patients with relapsed/refractory Hodgkin's disease: High survival rate in chemoresistant disease. A Southwest Oncology Group (SWOG) trial.
Other Clinical Trials
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
15%
Open
Phase